Amgen Inc. (NASDAQ:AMGN) Stake Boosted by Stokes Family Office LLC

Stokes Family Office LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,775 shares of the medical research company’s stock after acquiring an additional 44 shares during the quarter. Stokes Family Office LLC’s holdings in Amgen were worth $505,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. BIP Wealth LLC increased its stake in Amgen by 2.6% during the 4th quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock worth $360,000 after buying an additional 32 shares in the last quarter. Southland Equity Partners LLC increased its position in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after purchasing an additional 34 shares during the last quarter. Acropolis Investment Management LLC raised its position in Amgen by 3.5% in the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after purchasing an additional 34 shares during the period. Opal Wealth Advisors LLC boosted its holdings in Amgen by 1.9% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after acquiring an additional 34 shares during the period. Finally, Marino Stram & Associates LLC increased its stake in Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after buying an additional 34 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.69% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on AMGN. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Argus raised their price target on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. BMO Capital Markets raised their target price on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Mizuho boosted their price objective on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Finally, Royal Bank of Canada upped their price target on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $307.00.

Amgen Trading Up 1.8 %

Shares of AMGN stock traded up $5.74 during trading hours on Friday, reaching $330.83. The company had a trading volume of 2,191,011 shares, compared to its average volume of 2,717,037. The firm has a market cap of $177.47 billion, a price-to-earnings ratio of 46.88, a P/E/G ratio of 2.91 and a beta of 0.58. Amgen Inc. has a 1-year low of $224.34 and a 1-year high of $333.85. The company has a 50 day moving average of $308.79 and a 200 day moving average of $294.36. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $3.98 earnings per share. On average, equities research analysts anticipate that Amgen Inc. will post 19.47 EPS for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.